CLINICAL_TRIALS
trial_result
· 2015-08-10
Clinical Trial Update: Efficacy and Safety of Dovitinib in Patients With Gastrointestinal Stromal Tumors Refractory and/or Intolerant to Imatinib [Phase 2]
Summary
Phase 2 clinical trial evaluating the efficacy and safety of dovitinib in patients with gastrointestinal stromal tumors refractory and/or intolerant to imatinib…
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Novartis Pharmaceuticals | Conditions: Gastrointestinal Stromal Tumors | Phase 2 | Status: COMPLETED | Results posted: 2015-08-10